{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T22:50:00Z","timestamp":1778626200192,"version":"3.51.4"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T00:00:00Z","timestamp":1525737600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Gastroenterol"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1007\/s00535-018-1473-z","type":"journal-article","created":{"date-parts":[[2018,5,8]],"date-time":"2018-05-08T14:43:59Z","timestamp":1525790639000},"page":"1276-1284","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Real-world virological efficacy and safety of elbasvir and grazoprevir in patients with chronic hepatitis C virus genotype 1 infection in Japan"],"prefix":"10.1007","volume":"53","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-6168","authenticated-orcid":false,"given":"Hidenori","family":"Toyoda","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Takaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomonori","family":"Senoh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kojiro","family":"Michitaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Hiraoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinichi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chisa","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomomi","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruki","family":"Uojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshifumi","family":"Tada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirohito","family":"Yoneyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsunamasa","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Asano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toru","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideyuki","family":"Tamai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keizo","family":"Kato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kunihiko","family":"Tsuji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chikara","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Etsuko","family":"Iio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihiro","family":"Deguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Itobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Mikami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Moriya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironao","family":"Okubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joji","family":"Tani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhito","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Masaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takashi","family":"Kumada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,8]]},"reference":[{"key":"1473_CR1","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s12072-015-9629-x","volume":"9","author":"H Bennett","year":"2015","unstructured":"Bennett H, Waser N, Johnson K, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378\u201390.","journal-title":"Hepatol Int"},{"key":"1473_CR2","doi-asserted-by":"publisher","first-page":"875","DOI":"10.7326\/0003-4819-127-10-199711150-00003","volume":"127","author":"P Marcellin","year":"1997","unstructured":"Marcellin P, Boyer N, Gervais A, et al. Long-term histologic improvement and loss of detectable intrahepatic HCV RNA in patients with chronic hepatitis C and sustained response to interferon-alpha therapy. Ann Intern Med. 1997;127:875\u201381.","journal-title":"Ann Intern Med"},{"key":"1473_CR3","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1002\/hep.510260335","volume":"26","author":"ML Shiffman","year":"1997","unstructured":"Shiffman ML, Hofmann CM, Thompson EB, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology. 1997;26:780\u20135.","journal-title":"Hepatology"},{"key":"1473_CR4","doi-asserted-by":"publisher","first-page":"517","DOI":"10.7326\/0003-4819-132-7-200004040-00002","volume":"132","author":"Y Shiratori","year":"2000","unstructured":"Shiratori Y, Imazeki F, Moriyama M, et al. Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy. Ann Intern Med. 2000;132:517\u201324.","journal-title":"Ann Intern Med"},{"key":"1473_CR5","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1002\/hep.510290439","volume":"29","author":"K Ikeda","year":"1999","unstructured":"Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: a long-term observation study of 1643 patients using statistical bias correction with proportional hazard analysis. Hepatology. 1999;29:1124\u201330.","journal-title":"Hepatology"},{"key":"1473_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.7326\/0003-4819-129-2-199807150-00005","volume":"129","author":"Y Imai","year":"1998","unstructured":"Imai Y, Kawata S, Tamura S, et al. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Ann Intern Med. 1998;129:94\u20139.","journal-title":"Ann Intern Med"},{"key":"1473_CR7","doi-asserted-by":"publisher","first-page":"174","DOI":"10.7326\/0003-4819-131-3-199908030-00003","volume":"131","author":"H Yoshida","year":"1999","unstructured":"Yoshida H, Shiratori Y, Moriyama M, et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med. 1999;131:174\u201381.","journal-title":"Ann Intern Med"},{"key":"1473_CR8","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1002\/hep.510270529","volume":"27","author":"A Kasahara","year":"1998","unstructured":"Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 1998;27:1394\u2013402.","journal-title":"Hepatology"},{"key":"1473_CR9","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.jhep.2012.10.017","volume":"58","author":"E Ogawa","year":"2013","unstructured":"Ogawa E, Furusyo N, Kajiwara E, et al. Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma of patients with chronic hepatitis C: a prospective multicenter study. J Hepatol. 2013;58:495\u2013501.","journal-title":"J Hepatol"},{"key":"1473_CR10","doi-asserted-by":"publisher","first-page":"2584","DOI":"10.1001\/jama.2012.144878","volume":"308","author":"AJ Meer van der","year":"2012","unstructured":"van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584\u201393.","journal-title":"JAMA"},{"key":"1473_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1111\/liv.13071","volume":"36","author":"T Tada","year":"2016","unstructured":"Tada T, Kumada T, Toyoda H, et al. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis. Liver Int. 2016;36:817\u201326.","journal-title":"Liver Int"},{"key":"1473_CR12","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jhep.2016.11.012","volume":"66","author":"H Toyoda","year":"2017","unstructured":"Toyoda H, Kumada T, Tada T, et al. Efficacy and tolerability of an IFN-free regimen with DCV\/ASV for elderly patients infected with HCV genotype 1B. J Hepatol. 2017;66:521\u20137.","journal-title":"J Hepatol"},{"key":"1473_CR13","doi-asserted-by":"publisher","first-page":"E120","DOI":"10.1111\/hepr.12738","volume":"47","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Yamashita N, et al. Effectiveness and safety of daclatasvir plus asunaprevir for patients with hepatitis C virus genotype 1b aged 75\u00a0years and over with or without cirrhosis. Hepatol Res. 2017;47:E120\u201331.","journal-title":"Hepatol Res"},{"key":"1473_CR14","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1002\/jmv.24592","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Favorable efficacy of daclatasvir plus asunaprevir in treatment of elderly Japanese patients infected with HCV genotype 1b aged 70 and older. J Med Virol. 2017;89:91\u20138.","journal-title":"J Med Virol"},{"key":"1473_CR15","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1111\/jgh.13779","volume":"32","author":"M Ishigami","year":"2017","unstructured":"Ishigami M, Hayashi K, Honda T, et al. Daclatasvir and asunaprevir treatment in patients with severe liver fibrosis by hepatitis C virus genotype 1b infection: real-world data. J Gastroenterol Hepatol. 2017;32:1879\u201386.","journal-title":"J Gastroenterol Hepatol"},{"key":"1473_CR16","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1111\/hepr.12851","volume":"47","author":"G Suda","year":"2017","unstructured":"Suda G, Nagasaka A, Yamamoto Y, et al. Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus infected patients with renal impairment. Hepatol Res. 2017;47:1127\u201336.","journal-title":"Hepatol Res"},{"key":"1473_CR17","unstructured":"Arai T, Atsukawa M, Tsubota A, et al. Efficacy and safety of ombitasvir\/paritaprevir\/ritonavir therapy for genotype 1b chronic hepatitis C patients complicated with chronic kidney disease. Hepatol Res (in press)."},{"key":"1473_CR18","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s00535-016-1162-8","volume":"51","author":"G Suda","year":"2016","unstructured":"Suda G, Kudo M, Nagasaka A, et al. Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. J Gastroenterol. 2016;51:733\u201340.","journal-title":"J Gastroenterol"},{"key":"1473_CR19","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1007\/s00535-016-1174-4","volume":"51","author":"H Toyoda","year":"2016","unstructured":"Toyoda H, Kumada T, Tada T, et al. Safety and efficacy to dual direct-acting antiviral therapy (daclatasvir and asunaprevir) for chronic hepatitis C virus genotype 1 infection in patients on hemodialysis. J Gastroenterol. 2016;51:741\u20137.","journal-title":"J Gastroenterol"},{"key":"1473_CR20","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1111\/jvh.12553","volume":"23","author":"Y Kawakami","year":"2016","unstructured":"Kawakami Y, Imamura M, Ikeda H, et al. Pharmacokinetics, efficacy and safety of daclatasvir plus asunaprevir in dialysis patients with chronic hepatitis C: pilot study. J Viral Hepat. 2016;23:850\u20136.","journal-title":"J Viral Hepat"},{"key":"1473_CR21","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1007\/s00535-016-1285-y","volume":"52","author":"H Kumada","year":"2017","unstructured":"Kumada H, Suzuki Y, Karino Y, et al. The combination of elbasvir and grazoprevir for the treatment of chronic HCV infection in Japanese patients: a randomized phase II\/III study. J Gastroenterol. 2017;52:520\u201333.","journal-title":"J Gastroenterol"},{"key":"1473_CR22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1128\/JCM.35.1.201-207.1997","volume":"35","author":"O Ohno","year":"1997","unstructured":"Ohno O, Mizokami M, Wu RR, et al. New hepatitis C virus (HCV) genotyping system that allows for identification of HCV genotypes 1a, 1b, 2a, 2b, 3a, 3b, 4, 5a, and 6a. J Clin Microbiol. 1997;35:201\u20137.","journal-title":"J Clin Microbiol"},{"key":"1473_CR23","doi-asserted-by":"publisher","first-page":"e112647","DOI":"10.1371\/journal.pone.0112647","volume":"9","author":"Y Uchida","year":"2014","unstructured":"Uchida Y, Kouyama J, Naiki K, et al. A novel simple assay system to quantify the percent HCV RNA levels of NS5A Y93H mutant strains and Y93 wild-type strains relative to the total HCV-RNA levels to determine the indication for antiviral therapy with NS5A inhibitors. PLoS One. 2014;9:e112647.","journal-title":"PLoS One"},{"key":"1473_CR24","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1002\/hep.21178","volume":"43","author":"RK Sterling","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006;43:1317\u201325.","journal-title":"Hepatology"},{"key":"1473_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/hep.1840200104","volume":"20","author":"The French METAVIR Cooperative Study Group","year":"1994","unstructured":"The French METAVIR Cooperative Study Group. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology. 1994;20:15\u201320.","journal-title":"Hepatology"},{"key":"1473_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/hep.21669","volume":"46","author":"A Vallet-Pichard","year":"2007","unstructured":"Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. Comparison with liver biopsy and FibroTest. Hepatology. 2007;46:32\u20136.","journal-title":"Hepatology"},{"key":"1473_CR27","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1053\/j.ajkd.2008.12.034","volume":"53","author":"S Matsuo","year":"2009","unstructured":"Matsuo S, Imai E, Horio M, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982\u201392.","journal-title":"Am J Kidney Dis"},{"key":"1473_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/kisup.2012.73","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Grouop","year":"2013","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Grouop. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2013;3:1\u2013150.","journal-title":"Kidney Int"},{"key":"1473_CR29","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1159\/000448822","volume":"34","author":"S Hagiwara","year":"2016","unstructured":"Hagiwara S, Nishida N, Watanabe T, et al. Outcome of asunaprevir\/daclatasvir combination therapy for chronic liver disease type C. Dig Dis. 2016;34:620\u20136.","journal-title":"Dig Dis"},{"key":"1473_CR30","doi-asserted-by":"publisher","first-page":"e0163884","DOI":"10.1371\/journal.pone.0163884","volume":"11","author":"T Ide","year":"2016","unstructured":"Ide T, Eguchi Y, Harada M, et al. Evaluation of resistance-associated substitutions in NS5A using direct sequence and cycleave method and treatment outcome with daclatasvir and asunaprevir for chronic hepatitis C genotype 1. PLoS One. 2016;11:e0163884.","journal-title":"PLoS One"},{"key":"1473_CR31","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s00535-016-1225-x","volume":"52","author":"E Iio","year":"2017","unstructured":"Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir\/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2017;52:94\u2013103.","journal-title":"J Gastroenterol"},{"key":"1473_CR32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.4254\/wjh.v9.i25.1064","volume":"9","author":"H Fujii","year":"2017","unstructured":"Fujii H, Umemura A, Nishikawa T, et al. Real-world efficacy of daclatasvir and asunaprevir with respect to resistance-associated substitutions. World J Hepatol. 2017;9:1064\u201372.","journal-title":"World J Hepatol"},{"key":"1473_CR33","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.1111\/liv.13384","volume":"37","author":"H Sezaki","year":"2017","unstructured":"Sezaki H, Suzuki F, Hosaka T, et al. The efficacy and safety of dual oral therapy with daclatasvir and asunaprevir for genotype 1b in Japanese real-life settings. Liver Int. 2017;37:1325\u201333.","journal-title":"Liver Int"},{"key":"1473_CR34","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1002\/jmv.24617","volume":"89","author":"N Akuta","year":"2017","unstructured":"Akuta N, Sezaki H, Suzuki F, et al. Retreatment efficacy and predictors of ledipasvir plus sofosbuvir to HCV genotype 1 in Japan. J Med Virol. 2017;89:284\u201390.","journal-title":"J Med Virol"},{"key":"1473_CR35","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1007\/s00535-016-1290-1","volume":"52","author":"E Ogawa","year":"2017","unstructured":"Ogawa E, Furusyo N, Nomura H, et al. NS5A resistance-associated variants undermine the effectiveness of ledipasvir and sofosbuvir for cirrhotic patients infected with HCV genotype 1b. J Gastroenterol. 2017;52:845\u201354.","journal-title":"J Gastroenterol"},{"key":"1473_CR36","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1111\/hepr.12898","volume":"47","author":"E Iio","year":"2017","unstructured":"Iio E, Shimada N, Takaguchi K, et al. Clinical evaluation of sofosbuvir\/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir\/asunaprevir therapy. Hepatol Res. 2017;47:1308\u201316.","journal-title":"Hepatol Res"},{"key":"1473_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.3851\/IMP3117","volume":"22","author":"LI Backus","year":"2017","unstructured":"Backus LI, Belperio PS, Shahoumian TA, et al. Real-world effectiveness and predictors of sustained virological response with all-oral therapy in 21,242 hepatitis C genotype-1 patients. Antiviral Ther. 2017;22:481\u201393.","journal-title":"Antiviral Ther"},{"key":"1473_CR38","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1016\/j.jhep.2017.01.020","volume":"66","author":"SB Prenner","year":"2017","unstructured":"Prenner SB, VanWagner LB, Flamm SL, et al. Hepatocellular carcinoma decreases the chance of successful hepatitis C virus therapy with direct-acting antivirals. J Hepatol. 2017;66:1173\u201381.","journal-title":"J Hepatol"},{"key":"1473_CR39","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1002\/hep.27113","volume":"59","author":"H Kumada","year":"2014","unstructured":"Kumada H, Suzuki Y, Ikeda K, et al. Daclatasvir plus asunaprevir for chronic HCV genotype 1 infection. Hepatology. 2014;59:2083\u201391.","journal-title":"Hepatology"},{"key":"1473_CR40","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1002\/hep.27972","volume":"62","author":"H Kumada","year":"2015","unstructured":"Kumada H, Chayama K, Rodrigues L Jr, et al. Randomized phase 3 trial of ombitasvir\/paritaprevir\/ritonavir for HCV genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037\u201346.","journal-title":"Hepatology"},{"key":"1473_CR41","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1111\/jvh.12850","volume":"25","author":"R Kozuka","year":"2018","unstructured":"Kozuka R, Hai H, Motoyama H, et al. The presence of multiple NS5A RASs is associated with the outcome of sofosbuvir and ledipasvir therapy in NS5A inhibitor-na\u00efve patients with chronic HCV genotype 1b infection in a real-world cohort. J Viral Hepat. 2018;25:535\u201342.","journal-title":"J Viral Hepat."},{"key":"1473_CR42","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1007\/s00535-017-1396-0","volume":"53","author":"H Kumada","year":"2018","unstructured":"Kumada H, Watanabe T, Suzuki F, et al. Efficacy and safety of glecaprevir\/pibrentasvir in HCV-infected Japanese patients with prior DAA experience, severe renal impairment, or genotype 3 infection. J Gastroenterol. 2018;53:566\u201375.","journal-title":"J Gastroenterol"}],"container-title":["Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00535-018-1473-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1473-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00535-018-1473-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T18:40:55Z","timestamp":1604256055000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00535-018-1473-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,8]]},"references-count":42,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1473"],"URL":"https:\/\/doi.org\/10.1007\/s00535-018-1473-z","relation":{},"ISSN":["0944-1174","1435-5922"],"issn-type":[{"value":"0944-1174","type":"print"},{"value":"1435-5922","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,8]]},"assertion":[{"value":"13 February 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}